Levetiracetam is a modern solution to the problem of epilepsy in neuropediatric practice


  • L.B. Maryenko Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
  • K.M. Marienko Danylo Halytsky Lviv National Medical University, Lviv, Ukraine




levetiracetam, epilepsy, seizures, children


Levetiracetam is an antiepileptic drug, which has a fundamentally different mechanism of action among all drugs in this group. In vitro studies have shown that levetiracetam binds to the synaptic vesicles glycoprotein 2A contained in the gray matter of the brain and spinal cord. Thus, it affects the intraneuronal concentration of Ca2+ ions, partially inhibiting the Ca2+ flow through N-type channels and reducing the release of calcium from intraneuronal depots. In addition, levetiracetam partially restores flow through GABA- and glycine-dependent channels reduced by zinc and β-carbolines. Due to this, leviteracetam inhibits excessive neuronal synchronization and has an anticonvulsant effect. In neuropediatric practice, there is evidence that levetiracetam may be used as monotherapy to treat focal seizures with or without bilateral tonic-clonic seizures, as well as adjunctive therapy for myoclonic seizures in patients with juvenile myoclonic and idiopathic generalized epilepsy. At the same time, levetiracetam is characterized by rapid achievement of therapeutic effect and good tolerability in children and adolescents, as proven in many randomized clinical trials.


Download data is not yet available.


Fisher R.S., van Emde Boas W., Blume W. et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005. 46. 470-472.

Pellock J.M., Bourgeois Blaise F.D., Edwin Dodson W. et al. Pediatric Epilepsy. Diagnosis and treatment, third edition. NY: Demos, 2008. 895 p.

Хаузер В.А. Описательная эпидемиология эпилепсии. В кн.: Современная эпилептология: проблемы и решения. Под ред. Е.И. Гусева, А.Б. Гехт. М., 2015. C. 33-104.

Хобзей М.К., Зінченко О.М., Голубчиков М.В., Міщенко Т.С. Стан неврологічної служби України у 2009 році. Новости медицины и фармации. 2010. 10.

Marik P.E., Varon J. The Management of Status Epilepticus. Chest. 2004. 126. 582-591.

Lyseng-Williamson K.A. Spotlight on levetiracetam in epilepsy. CNS Drugs. 2011. 25(10). 901-5.

Гузева В.И., Гузева В.В., Гузева О.В. Профилактика ­осложнений и оценка безопасности антиэпилептической терапии у детей. В кн.: Современная эпилептология: проблемы и решения. Под ред. Е.И. Гусева, А.Б. Гехт. М., 2015. 471-89.

Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002. 43. 1. 9-18.

Noyer M., Gillard M., Matagne A. et al. The novel antiepileptic drug levetiracetam (UCB LO59) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 1995. 286. 137-146.

Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clinical Pharmacokinetics. 2006. 45. 351-363.

Gorji A., Hohling J.M., Madeja M. et al. Effect of levetiracetam on epileptiform discharges in human neocortical slices. Epilepsia. 2002. 43. 12. 1480-1487.

Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000. 85. 77-85.

Мухин К.Ю., Пылаева О.А. Эффективность и переносимость леветирацетама в лечении эпилепсии. НейроNEWS. 2014. 7 (62).

Merhar S., Schibler K., Sherwin C., Meinzen-Derr J., Shi J., Balmakund T., Vinks A. Pharmacokinetics of levetiracetam in neonates with seizures. J. Pediatr. 2011. 159(1). 152-154.

Sharpe С., Capparelli E., Mower A., Farrell M., Soldin S., Haas R. A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of live. Pediatric Research. 2012. 72. 43-49.

Glauser T., Mitchell W., Weinstock A., Bebin M., Chen D., Coupez R., Stockis A., Lu Z. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia. 2007. 48(6). 1117-1122.

Dahlin M., Wide K., Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. Pediatr. Neurol. 2010. 43(4). 231-235.

Sinha J., Karatza E., Gonzalez D. Physiologically-based pharmacokinetic modeling of oxcarbazepine and levetiracetam du­ring adjunctive antiepileptic therapy in children and adolescents. CPT Pharmacometrics Syst. Pharmacol. 2021 Nov 23. doi: 10.1002/psp4.12750.

Lyseng-Williamson K.A. Levetiracetam: a review of its use in epilepsy. Drugs. 2011. 71(4). 489-514.

Perry M., Benatar M. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review. Epilepsia. 2007. 48(6). 1123-1127.

Krief P., Kan L., Maytal J. Efficacy of Levetiracetam in Children with Epilepsy Younger Than 2 Years of Age. J. Child Neurol. 2008. 23. 582-58.

Piсa-Garza J., Nordli D., Rating D., Yang H., Schiemann-Delgado J., Duncan B. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia. 2009. 50(5). 1141-1149.

Piсa-Garza J., Schiemann-Delgado J., Yang H., Duncan B., Hadac J., Hunter S. Adjunctive levetiracetam in patients aged 1 month to < 4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks. Clin. Ther. 2010. 32(11). 1935-1950.

Akter N., Rahman M.M., Akhter S., Fatema K. A Randomized Controlled Trial of Phenobarbital and Levetiracetam in Childhood Epilepsy. Mymensingh Med. J. 2018 Oct. 27(4). 776-784. PMID: 30487494.

Johnson М.Е., McClung С., Bozorg А. Analyses of seizure responses supportive of a novel trial design to assess efficacy of antiepileptic drugs in infants and young children with epilepsy: Post hoc analyses of pediatric levetiracetam and lacosamide trials. Epilepsia Open. 2021. 6(2). 359-368.

Shorvon S., Perucca E. The Treatment of Epilepsy. 2009. 559-574.

Furwentsches A., Bussmann C., Ramantani G. et al. Levetiracetam in the treatment of neonatal seizures: A pilot study. Seizure. 2010. 19. 185-189.

Khan O., Chang E., Cipriani C., Wright C., Crisp E., Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr. Neurol. 2011. 44(4). 265-269.

Ramantani G., Ikonomidou C., Walter B., Rating D., Din­ger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur. J. Paediatr. Neurol. 2011. 15(1). 1-7.

Abend N., Gutierrez-Colina A., Monk H., Dlugos D., Clancy R. Levetiracetam for Treatment of Neonatal Seizures. J. Child Neurol. 2011. 26(4). 465-470.

Wheless J., Clarke D., Hovinga C. et al. Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study. J. Child Neurol. 2009. 24. 946-951.

Qiao M.Y., Cui H.Т., Zhao L.Z., Miao J.K., Chen Q.X. Efficacy and Safety of Levetiracetam vs. Phenobarbital for Neonatal Seizures: A Systematic Review and Meta-Analysis. Front. Neurol. 2021 Nov 18. 12. 747745. doi: 10.3389/fneur.2021.747745. PMID: 34867732; PMCID: PMC8636327.

Morrell M.J., Leppik I., French J., Ferrendelli J., Han J., Magnus L. The KEEPER trial: Levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 2003. 54. 153-61.

Grosso S., Franzoni E., Coppola G., Iannetti P., Verrotti A., Cordelli D., Marchiani V., Pascotto A., Spalice A., Acampora B., Morgese G., Balestri P. Efficacy and safety of levetiracetam: an ad-don trial in children with refractory epilepsy. Seizure. 2005. 14(4). 248-53.

Peake D., Mordekar S., Gosalakkal J. et al. Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Seizure. 2007. 16(2). 185-9.

Li S., Cao J., Xiao N., Cai F. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J. Child Neurol. 2010. 25(5). 609-613.

Hu Y., Liao J., Chen L., Huang T., Li B. Efficacy and safety of adjunctive levetiracetam in children younger than 4 years with refractory epilepsy. Zhongguo Dang Dai Er Ke Za Zhi. 2010. 12(4). 256-258.

Chhun S., Troude P., Villeneuve N., Soufflet C., Napuri S., Motte J., Pouplard F., Alberti C., Helfen S., Pons G., Dulac O., Chiron C. A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target. Seizure. 2011. 20(4). 320-325. DOI: 10.1016/j.seizure. https://pubmed.ncbi.nlm.nih.gov/21256770/

Doumbia-Ouattara M. et al. Experience with levetiracetam in the treatment of childhood refractory epilepsy. Arch. Pediatr. 2012. 19(1). 3-8.

Lee Y., Kang H., Kim H., Lee J. Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy. Pediatr. Neurol. 2010. 42(2). 86-92.

Mahmoud A., Tabassum S., Al Enazi S., Lubbad N., Al Wadei A., Al Otaibi A., Jad L., Benini R. Amelioration of Levetiracetam-Induced Behavioral Side Effects by Pyridoxine. A Randomized Double Blind Controlled Study. Pediatr. Neurol. 2021 Jun. 119. 15-21. doi: 10.1016/j.pediatrneurol.2021.02.010. Epub 2021 Mar 8. PMID: 33823377.

Labate A., Colosimo E., Gambardella A., Leggio U., Ambrosio R., Quattrone A. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure. 2006 Apr. 15(3). 214-8. doi: 10.1016/j.seizure.2005.12.004. Epub 2006 Jan 18. PMID: 16420982.

Specchio N., Boero G., Michelucci R. et al. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Epilepsia. 2008. 49(4). 663-9.

Sharpe D.V., Patel A.D., Abou-Khalil B., Fenichel G.M. Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure. 2008. 17(1). 64-8.

Lagae L., Buyse G., Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an addon and monotherapy trial. Seizure. 2005. 14. 6671.



How to Cite

Maryenko, L., & Marienko, K. (2022). Levetiracetam is a modern solution to the problem of epilepsy in neuropediatric practice. INTERNATIONAL NEUROLOGICAL JOURNAL, 18(1), 54–62. https://doi.org/10.22141/2224-0713.18.1.2022.930



Original Researches